Kluczowym skadnikiem produktu jest biako BPC-157 , ktre w postaci doustnej nie ulega stratom w przewodzie pokarmowym, a dziki swoim waciwoci nazywany jest Zwizkiem Ochrony Ciaa
CagriSema FDA approval timeline Novo Nordisk submitted the New Drug Application (NDA) to the FDA on December 18, 2025 , for chronic weight management in adults with obesity or overweight with a weight-related comorbidity
Food & Drug Administration
Lipoprotein (a) has been called a powerful predictor of premature atherosclerotic vascular disease
The effects on blood pressure and thrombocytes function maintenance [78,80,81] are suggestive, BPC 157 may counteract induced hypertension and pro-thrombotic effect (L-NAME), and induced hypotension [78,81] and anti-thrombotic (L-arginine) effect [81], and finally, exert a vasomotor tone carried out through BPC 157 specific activation of Src-Caveolin-1-endothelial nitric oxide synthase (eNOS) pathway [47]
Regular sessions are recommended to maintain optimal nutrient levels and sustained health benefits.
